Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn’s Disease (Versus-CD): Data from the ENEIDA Registry
Journal of Crohn's and Colitis · 27.01.2024 · 18 (1) · 65-74
DOI: 10.1093/ecco-jcc/jjad124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 31.07.2023. Verfasst von María José García und 49 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Valdec…. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Spanish Working Group in Crohn's Disease and Ulcerative Colitis, Spanish Working Group in Crohn’s Disease and Ulcerative Colitis.
Abstract (Originalsprache)
Background
Both vedolizumab and ustekinumab are approved for the management of Crohn’s disease [CD]. Data on which one would be the most beneficial option when anti-tumour necrosis factor [anti-TNF] agents fail are limited.
Aims
To compare the durability, effectiveness, and safety of vedolizumab and ustekinumab after anti-TNF failure or intolerance in CD.
Methods
CD patients from the ENEIDA registry who received vedolizumab or ustekinumab after anti-TNF failure or intolerance were included. Durability and effectiveness were evaluated in both the short and the long term. Effectiveness was defined according to the Harvey–Bradshaw index [HBI]. The safety profile was compared between the two treatments. The propensity score was calculated by the inverse probability weighting method to balance confounder factors.
Results
A total of 835 patients from 30 centres were included, 207 treated with vedolizumab and 628 with ustekinumab. Dose intensification was performed in 295 patients. Vedolizumab [vs ustekinumab] was associated with a higher risk of treatment discontinuation (hazard ratio [HR] 2.55, 95% confidence interval [CI]: 2.02–3.21), adjusted by corticosteroids at baseline [HR 1.27; 95% CI: 1.00–1.62], moderate–severe activity in HBI [HR 1.79; 95% CI: 1.20–2.48], and high levels of C-reactive protein at baseline [HR 1.06; 95% CI: 1.02–1.10]. The inverse probability weighting method confirmed these results. Clinical response, remission, and corticosteroid-free clinical remission were higher with ustekinumab than with vedolizumab. Both drugs had a low risk of adverse events with no differences between them.
Conclusion
In CD patients who have failed anti-TNF agents, ustekinumab seems to be superior to vedolizumab in terms of durability and effectiveness in clinical practice. The safety profile is good and similar for both treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
- Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades He…
- Gastroenterology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
- IBD Unit, Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain.
- Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
- Gastroenterology Department, Hospital Álvaro Cunqueiro, Vigo, Spain.
ORCID-Profile: María José García, Agnès Fernández-Clotet, Francisco Mesonero, María José Casanova, Manuel Barreiro-de Acosta, Sabino Riestra, Fernando Bermejo, Carlos González Muñoza, Eugeni Domènech, María Chaparro, Javier P Gisbert
Förderung
- Spanish Working Group in Crohn's Disease and Ulcerative Colitis
- Spanish Working Group in Crohn’s Disease and Ulcerative Colitis
Zitieren
APA
García, M. J., Rivero, M., Fernández-Clotet, A., de Francisco, R., Sicilia, B., Mesonero, F., de Castro, M. L., Casanova, M. J., Bertoletti, F., García-Alonso, F. J., López-García, A., Vicente, R., Calvet, X., Barreiro-de Acosta, M., Ferrer Rosique, J., Varela Trastoy, P., Nuñez, A., Ricart, E., Riestra, S., …, & Gisbert, J. P. (2024). Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn’s Disease (Versus-CD): Data from the ENEIDA Registry. Journal of Crohn's and Colitis, 18(1), 65-74. https://doi.org/10.1093/ecco-jcc/jjad124
Vancouver
García MJ, Rivero M, Fernández-Clotet A, de Francisco R, Sicilia B, Mesonero F, et al. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn’s Disease (Versus-CD): Data from the ENEIDA Registry. Journal of Crohn's and Colitis. 2024;18(1):65-74. doi:10.1093/ecco-jcc/jjad124
BibTeX
@article{Garca2024,
author = {García, María José and Rivero, Montserrat and Fernández-Clotet, Agnès and de Francisco, Ruth and Sicilia, Beatriz and Mesonero, Francisco and de Castro, María Luisa and Casanova, María José and Bertoletti, Federico and García-Alonso, Francisco Javier and López-García, Alicia and Vicente, Raquel and Calvet, Xavier and Barreiro-de Acosta, Manuel and Ferrer Rosique, Juan and Varela Trastoy, Pilar and Nuñez, Alejandro and Ricart, Elena and Riestra, Sabino and Arias García, Lara and Rodríguez, María and Arranz, Laura and Pajares, Ramón and Mena, Raquel and Calafat, Margalida and Camo, Patricia and Bermejo, Fernando and Ponferrada, Ángel and Madrigal, Rosa Eva and Llaó, Jordina and Sesé, Eva and Sánchez, Eugenia and Pineda Mariño, Juan Ramón and González Muñoza, Carlos and Carbajo López, Ana Yaiza and Julián, Ana Belén and Villoria Ferrer, Albert and Baston-Rey, Iria and Jara, Lorena and Almela, Pedro and Codesido, Laura and de la Maza, Saioa and Leal, Carles and Caballol, Berta and Pérez-Martínez, Isabel and Vinuesa Campo, Raquel and Crespo, Javier and Domènech, Eugeni and Chaparro, María and Gisbert, Javier P},
title = {Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn’s Disease (Versus-CD): Data from the ENEIDA Registry},
journal = {Journal of Crohn's and Colitis},
year = {2024},
volume = {18},
number = {1},
pages = {65--74},
doi = {10.1093/ecco-jcc/jjad124}
}
EUVIMED